Farxiga Tablet, Film Coated
NDC Package 50090-3482-0
Package Information
Farxiga (dapagliflozin) tablets is fARXIGA (dapagliflozin) is indicated:•To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.•To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.•To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.•As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.Limitations of Use•FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1)].•FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m2. This formulation utilizes a tablet, film coated delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-3482 and is authorized under FDA application NDA202293.
Identification & Billing
- RxCUI: 1486977 - farxiga 10 MG Oral Tablet
- RxCUI: 1486977 - dapagliflozin 10 MG Oral Tablet [Farxiga]
- RxCUI: 1486977 - Farxiga 10 MG Oral Tablet
- RxCUI: 1486981 - farxiga 5 MG Oral Tablet
- RxCUI: 1486981 - dapagliflozin 5 MG Oral Tablet [Farxiga]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-3482 - Farxiga
- 50090-3482-0 - 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 50090-3482 - Farxiga
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-3482-0 identifies a specific commercial package of 30 tablet, film coated in 1 bottle, plastic of Farxiga, a human prescription drug labeled by A-s Medication Solutions. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet, film coated is formulated for oral use and contains dapagliflozin propanediol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on January 14, 2008. The current certification is valid through December 31, 2027.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090348200. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.